Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Praha 8, Czechia Clinical Trials

A listing of Praha 8, Czechia clinical trials actively recruiting patients volunteers.

RESULTS

Found (16) clinical trials

A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients

This posting discloses information about Part 1 of CCSJ137X2201. Another part, Part 2, of this trial is planned for conduct subsequent to the initiation of Part 1 and will have a different design than Part 1. The details of the design for this additional part are planned for disclosure in ...

Phase

2.67 miles

Learn More »

Study to Assess the Safety Pharmacokinetics and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

This is a Phase 1b/2, double-blind (Principal Investigators and study subjects blinded, Sponsor unblinded), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in subjects with Acute Ischemic Stroke (AIS).

Phase

2.67 miles

Learn More »

Dose Escalation Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion, multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel, or versus docetaxel in FGFR3 mutant/fusion subjects with Stage IV, locally advanced or metastatic UCC who have relapsed after, or are refractory to at least one ...

Phase

2.67 miles

Learn More »

A Phase I/II Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

Study Description: All patients who fulfill all eligibility criteria will undergo a leukapheresis procedure. ONCOS-102 administration will start within 3 weeks of leukapheresis at Week 5 (35 days since baseline +/- 2 days), and 3 further doses will be administered on a weekly basis Cyclophosphamide A priming bolus dose of ...

Phase

2.67 miles

Learn More »

Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM

This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma following 1-4 lines of prior therapy. Patients will receive either melflufen+dexamethasone+bortezomib or melflufen+dexamethasone+daratumumab and are required to be PI refractory to be enrolled to the bortezomib regimen, and to not have any ...

Phase

2.67 miles

Learn More »

A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer

Protein-lipid complexes represent a new type of tumouricidal biologicals, with broad effects against cancers of different origins. The investigational product alpha1H is a synthetic peptide, corresponding to the alpha1 domain of -lactalbumin, in complex with oleic acid. Alpha1H is a further development product of HAMLET, a complex between human alpha-lactalbumin ...

Phase

2.67 miles

Learn More »

The FIERCE-21 study is a Phase 1/2(b) study to evaluate the effectiveness and safety of Vofatamab  alone (monotherapy) and vofatamab plus docetaxel versus placebo plus docetaxel in the treatment of subjects with Stage IV, locally advanced or metastatic FGFR mutation positive UCC who have previously been treated for their bladder ...

Phase

2.67 miles

Learn More »

The eMESH 1 Feasibility Study

Multi-center, dual cohort (randomized and single vessel) study designed to demonstrate feasibility, initial safety and performance of the Kips Bay Medical, Inc. eSVS Mesh as an external vein support device for use over saphenous vein grafts during coronary artery bypass surgery. In the Randomized Cohort, each study subject will receive ...

Phase

2.67 miles

Learn More »

A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)

This is an adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/L on two counts no sooner than 7 days apart in the 15 days before treatment begins. The active treatment period ...

Phase

2.67 miles

Learn More »

A Phase Ib/II Multicenter Single Arm Open-Label Study To Evaluate the Safety Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study

This study will test the safety and effectiveness of a combination of investigational new drug called BL-8040 and atezolizumab to find out what effects, good or bad, this treatment has on medical condition. Atezolizumab is manufactured by Roche and is approved by FDA for other indications while BL-8040 is in ...

Phase

2.67 miles

Learn More »